A St. Louis judge has cleared the way for the first jury trial involving personal injuries allegedly caused by Medtronic's Infuse Bone Graft.
The injury claims of plaintiff Trisha Keim are set for trial in February, after Judge Mark H. Neill of Missouri's 22nd Judicial Circuit declined to dismiss the case or transfer it to another court.
A trial in the case has the potential to make public heretofore sealed records that would be available to thousands of other pending injury cases involving Infuse, a bone-fusion product that has been used on more than a million patients since 2002.
Product liability expert David Prince of the Mitchell Hamline School of Law called Neill's Dec. 2 order "a very big deal."
"They've got all the discovery [documents]," Prince explained. A trial "means all of this information will come into the public record with all of these other plaintiffs standing in line. This is always the point where a defendant has to have a come-to-Jesus meeting with himself. Do I take a chance or do I settle? There's a lot at stake. This is as much a business decision as anything else."
In a statement to the Star Tribune, Medtronic spokesman Eric Epperson said, "Judge Neill's ruling merely permits this case to proceed to trial; it does not decide the merits of the claim. Medtronic believes the claims in this case are baseless, and we are prepared to vigorously defend ourselves in court."
Medtronic cannot appeal Neill's ruling before the case goes to trial. The company has said in regulatory filings that it has already spent more than $100 million settling Infuse injury litigation ahead of trial.
Settlement documents in some cases stipulate that many documents remain secret and that the injured cannot talk about their cases. Medtronic also reached an $89 million settlement in a shareholder suit alleging that improper Infuse marketing hurt the company's stock price.